R3R01 ( DrugBank: - )

---

2 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
218	アルポート症候群	1
222	一次性ネフローゼ症候群	1

218. アルポート症候群

---

臨床試験数 : 26 /  薬物数 : 33 - (DrugBank : 13) / 標的遺伝子数 : 6 - 標的パスウェイ数 : 29

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05267262 (ClinicalTrials.gov)	March 15, 2022	23/2/2022	Study to Evaluate R3R01 in Patients With Alport Syndrome and Patients With Focal Segmental Glomerulosclerosis	A Phase II, Multi-center, Open-Label Study to Assess Safety, Tolerability, Efficacy and Pharmacokinetics of R3R01 in AS Patients With Uncontrolled Proteinuria on ACE/ARB Inhibition and in Patients With Primary Steroid-Resistant FSGC	Alport Syndrome;Focal Segmental Glomerulosclerosis	Drug: R3R01	River 3 Renal Corp.	IQVIA Biotech	Not yet recruiting	12 Years	N/A	All	50	Phase 2	NULL

222. 一次性ネフローゼ症候群

---

臨床試験数 : 285 /  薬物数 : 285 - (DrugBank : 108) / 標的遺伝子数 : 62 - 標的パスウェイ数 : 191

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05267262 (ClinicalTrials.gov)	March 15, 2022	23/2/2022	Study to Evaluate R3R01 in Patients With Alport Syndrome and Patients With Focal Segmental Glomerulosclerosis	A Phase II, Multi-center, Open-Label Study to Assess Safety, Tolerability, Efficacy and Pharmacokinetics of R3R01 in AS Patients With Uncontrolled Proteinuria on ACE/ARB Inhibition and in Patients With Primary Steroid-Resistant FSGC	Alport Syndrome;Focal Segmental Glomerulosclerosis	Drug: R3R01	River 3 Renal Corp.	IQVIA Biotech	Not yet recruiting	12 Years	N/A	All	50	Phase 2	NULL